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[Abstract] 
Historically, small molecules, including steroid hormones and cytokines, have been attributed a role 
in paracrine and endocrine signaling, and now include a new player: biological nanoparticles, or 
‘exosomes’. Generated intracellularly, and defined simply as nano-particulate packages of signaling 
moieties, exosomes have emerged as vehicles for highly specialized local and distant intercellular 
communication. Exosomes are increasingly being recognized as contributing factors in many diseases, 
and their potential as biomarkers and in therapeutics is rapidly emerging. This review highlights recent 
advances in the exploitation of exosomes in diagnostic and therapeutic applications. We discuss 
various facets of nanoparticles, namely, the isolation and manipulation of exosomes, the construction 
of synthetic exosome-like particles in vivo, and their potential use in the treatment of various diseases. 
Trends box  
·        Exosome diagnostics, although available, remain un-approved by regulatory agencies, and thus, 
might be used in parallel with existing approved tests. 
·        Exosome approaches to therapeutic interventions are far-reaching; from packaging of 
therapeutic agents, to driving immune responses. Applications range from oncology to regenerative 
medicine, and commercial GMP production at therapeutically relevant quantities is underway. 
·        Exosomes can trigger positive and negative immunomodulatory effects, as observed in early 
exosome clinical trials for advanced non-small cell lung cancer, thus potentially impacting on disease 
progression. 
·        The effects of MSC delivery to patients showing therapeutic benefit appear to be exosome-
derived as exosomes purified from MSCs can promote similar effects to MSC based treatments. 
·        The potential for tumor-derived exosomes to control the establishment of organ-specific pre-
metastatic niche has been demonstrated through their ability to program bone marrow-derived cells 
towards a pro-metastatic phenotype. 
 
 
2 
 
 
Exploring the Clinical Potential of Exosomes 
Cellular communication pathways include direct cell-to-cell contact, inter-cellular molecular 
messengers and exosomes. These 30-130 nm membrane bound nanoparticles harboring biomolecular 
payloads, offer significant potential in both detecting and treating diseases. Efforts to capture the 
exosomes’ potential are far reaching, from trans-species signaling to immune-system priming and 
drug delivery. Moreover, understanding any side-effects of their use in humans is essential. Whilst the 
complexities surrounding their therapeutic potential continue to be unraveled, the use of exosomes 
as diagnostic tools is underway, with prostate cancer exosome diagnostics being used alongside FDA 
approved tests. Clinical trials have evaluated the therapeutic potential of exosomes, and whilst 
demonstrating safety, have yet to show efficacy (Tables 1-3). Trials have largely involved using 
manipulated exosomes, rather than harnessing properties of native exosomes. For example, 
autologous dendritic cell-derived exosomes loaded with MAGE (Melanoma Associated Antigen) 
peptides are being used in a Phase II non-small cell lung cancer trial (clinicaltrials.gov/NCT01159288). 
In contrast, some biotechnology companies are producing exosomes from non-engineered stem cells, 
which necessitates research into the inherent mechanisms by which native exosomes target specific 
tissues and cell types, and an understanding of how tissues recognize such nanoparticles. The 
development of therapeutic exosomes will likely follow both paths, and require refined approaches 
for exosome isolation, programming of exosomes in vivo using genetic or epigenetic approaches, 
encapsulating therapeutics within purified exosomes, or the synthesis of semi-synthetic, more highly 
defined exosome-like therapeutic nano-vehicles (Figure 1). Using these approaches, it may become 
possible to tailor exosome-based therapeutics to treat disease. Here, we provide a review of exosome 
biogenesis and structure, before considering therapeutic and other applications. Finally, we consider 
the dynamic nature of exosomes and their interactions in vivo, before concluding how synthetic 
exosomes may overcome some of the limitations of native exosomes in therapeutic applications.  
 
Exosome Structure and Composition 
Exosomes have an aqueous core and lipophilic shell, and their amphiphilic properties enable them to 
compartmentalize and solubilize both native and introduced hydrophilic and hydrophobic materials 
(Box 1) [1]. Cargos include proteins, lipids, and RNAs that can be distinct from the cell’s endocytic 
origin. The endocytic origin includes endosomal proteins involved in transport and fusion (annexins 
and flotillin), cell targeting (tetraspanins), multi-vesicular body (MVB) proteins (Alix and TSG101) [2], 
as well as various proteins linked to lipid metabolism [3]. Extracellular matrix and cell surface proteins 
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such as collagens, integrins, and galectins [4], cell surface receptors and signaling molecules, 
intracellular cytoskeletal components, as well as metabolic enzymes and G proteins are also present 
[5]. In contrast to their cells of origin, exosomes are enriched in cholesterol, ceramide, 
phosphoglycerides, and long and saturated fatty-acyl chains, all of which may provide structural 
stability [2]. Morphologically distinct MVBs within the same cell result in distinctive exosome 
populations with unique molecular and biophysical characteristics [6,7]. Differences and changes in 
exosome composition are widely observed in vitro and in vivo in response to localized environmental 
conditions. For instance, inflammatory signals including lipopolysaccharides, TNFα, and IFNγ strongly 
affect the composition of exosomes released by dendritic [8] or mesenchymal stem cells [9]. Hypoxia, 
observed in the core of large tumors can modify exosome composition of human endothelial [10] and 
patient-matched glioblastoma multiforme tumor [11] cells.  
 
 
Exosomes: Function and Design 
Exosomes satisfy a number of design criteria, including the ability to package small chemical and 
biomolecular agents, cross biological barriers such as the blood brain barrier [12]. Structural 
characteristics such as size, shape, and surface properties (surface charge/chemistry and ligand 
density) directly impact on their behavior in complex processes including protein opsonization, blood 
circulation, tissue penetration, cell interaction, and renal clearance [1]. For example, the size of nano-
particles used in systematic delivery should be large enough to avoid rapid renal clearance, and small 
enough to evade reticuloendothelial system (RES) uptake, as determined in mice  [13]. Moreover, for 
human cancer therapy such as Doxil® (PEGylated nano-liposomes), particles of 10–100 nm in diameter 
can take advantage of tumoral vascular alterations to passively reach the tumor site, through 
enhanced permeability and retention effects [14]. In addition, net surface charge determines the 
colloidal stability of nanoparticles and their interactions with biological systems [15]. Positively 
charged nanoparticles undergo fast protein opsonization, and are quickly cleared by RES from blood 
circulation by murine RAW264.7 macrophages, whereas neutral or slightly negative surfaces reduce 
RES clearance to provide more efficient delivery to tumor sites in SKOV-3 human ovarian cancer 
xenograft mouse models [16]. 
 
Exosomes in Health and Disease 
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In humans, exosomes play pivotal roles in normal physiological and pathological conditions (Figure 1) 
[29–31], through long range signaling via blood, cerebrospinal fluid, and breast milk to modulate 
target cell behavior [32,33]. Exosomes drive multiple biological processes including modulation of 
gene expression via RNA intercellular transfer [34] and immuno-suppressive or immuno-stimulating 
responses [35–37]. Moreover, these nanovesicles have been implicated in antigen presentation and T 
cell activation in different contexts, including in vivo bacterial infections [17]. The role of exosomes in 
angiogenesis has also been acknowledged and recent studies have suggested that exosomes present 
in human pericardial fluid can enhance therapeutic angiogenesis and vascular repair in ischemic mice 
[18]. This beneficial effect has also been observed for normal cardiovascular physiology, with 
mesenchymal stem cell (MSC)-derived exosomes conferring cardioprotection in mice, as 
demonstrated by reduced myocardial ischemia/reperfusion injury of such exosome-treated animals 
[19]. By contrast, human monocyte-derived exosomes have been found to induce programmed cell 
death of vascular smooth muscle cells under inflammatory conditions [20], an important process in 
human vascular diseases. 
 
In cancer, tumor-derived exosomes have been shown to induce apoptosis of human pancreatic tumor 
cells [21] while inducing apoptosis of cytotoxic T lymphocytes as a tumor escape mechanism in an in 
vitro model of prostate cancer cell lines [22]. It has been further suggested that exosomes might favor 
or counteract tumor progression via dissemination of oncogenes or tumor suppressors between cells, 
in a context-dependent manner [23]. Moreover, in diseases such as pancreatic ductal adenocarcinoma 
(PDAC), tumor dissemination may involve the mechanistic contribution of exosomes to form pre-
metastatic niches, as was determined in the liver of PDAC patients [24]. Of note, because exosomes 
can naturally cross the plasma membrane of recipient cells [25], their manipulation can lead to 
therapeutic molecule delivery in a selective manner, for example in mouse αv integrin-positive breast 
cancer cells [26]. Moreover, aside from being able to efficiently cross the blood-brain-barrier to induce 
potentially significant therapeutic effects [27] in contrast to most non-engineered small molecule 
drugs, exosomes can also be modified or functionalized with the addition of tumor target ligands, as 
has been proposed for folic acid to promote tumor size reduction in a human lung cancer mouse 
xenograft model [28].  
As for pathogen infections, these biological nanoparticles might either function as clearing vehicles to 
expel invading bacteria from infected cells [29], or as vector-transmitted virulence factors to spread 
infections, as in the case of cutaneous leishmaniasis [30]. Due to the heterogeneity of induced 
biological effects on recipient cells, which appear to be triggered by distinct exosome subpopulations 
with unique molecular compositions [22], exosomes may open new avenues for exosome-based 
diagnostics and innovative therapeutic strategies. 
 
Strategies for Therapeutic Deployment of Exosomes 
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Native Exosomes  
Cells introduced into recipients to exploit native exosomes for disease treatment potentially offer the 
most direct route to exosome therapeutics. Exosomes from stimulated platelets have been shown to 
play a role in athero-thrombotic processes, impeding platelet aggregation and reducing levels of the 
platelet activator CD36, which might be considered as a potential therapeutic option of suppressing 
occlusive thrombosis [31].  Similarly, when secreted from mesenchymal stem cell (MSCs), exosomes 
appear to be significant effectors of MSC responses, rather than influencing the differentiation of 
MSCs in tissue repair [32]. For instance, MSC-derived exosomes have demonstrated cardiac and 
vascular benefits, including suppression of pulmonary hypertension (PH), vascular remodeling and 
inflammation in murine models of PH [32], as well as modulating angiogenesis in a human placental 
endothelial cell in vitro model [33]. Furthermore, exosomes derived from rat bone marrow MSCs have 
been reported to protect cardiomyocytes from ischemic injury in a rat model of myocardial infarction 
[34]. Human MSCs, isolated from bone marrow or adipose tissue appear to produce native exosomes 
with a wide range of effects, including regenerative capacities in cutaneous wound healing in a mouse 
model of skin incision [35] and skeletal muscle regeneration in  mouse model of muscle injury [36]. 
However, the mechanism of action of these effects remains to be characterized, and caution must be 
exercised until specific effector molecule(s) contained within MSC-derived exosomes along with their 
mechanistic role are identified [37]. 
 
Modification of Content via Parent Cell Treatment 
Treatment of cells to produce modified exosome content in order elicit a disease specific response has 
produced significant advances; this has been achieved either through exposure to various exogenous 
compounds such as cytokines, and gene transfection or stable genetic manipulation of the exosome-
producing parent cell (Box 2). Specifically, treatment of human platelets with aspirin has resulted in a 
decrease in cargo protein levels in platelet-derived exosomes, without altering total levels of exosome 
numbers [38]. Furthermore, murine bone marrow derived dendritic cells treated with recombinant 
murine IL-10 protein, have produced exosomes harboring a significant immunosuppressive effect, as 
demonstrated in a delayed-type hypersensitivity mouse model leading to reduced inflammation,  or 
in a murine collagen-induced arthritis model where the onset was reversed/repressed[39]. Another 
study documented that human vascular smooth muscle cells, engineered to carry fetuin-A (a 
calcification inhibitor), produced this factor which could be encapsulated in the cell-derived exosome 
MVs, which triggered vascular calcification under extracellular calcifying conditions in vitro [40]. 
Others initially reported that pulsing murine dendritic cells (DCs) with tumor peptides resulted in an 
increased ability of DC-derived exosomes to prime cytotoxic T cell immune responses against murine 
tumors [41]. Content can also be modified via cell transfection to deliver proteins and nucleic acids 
into exosomes;  for example, upon transfection of synthetic double-strand miR-143 microRNA into 
human MSCs, exosome-formed miR-143 was shown to be secreted extracellularly from exosomes, 
and subsequently transferred into osteosarcoma cells, suppressing cell migration in vitro [42].  
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In addition, recent research has demonstrated that treatment of human ovarian cancer with sub-
cytotoxic levels of decitabine --  a DNA methyltransferase (DNMT)  epigenetic inhibitor (used to treat 
myelodysplastic syndromes and acute myeloid leukemia), --triggered cytokine release from tumor 
cells; this resulted in cytotoxic T cell recruitment and immune-cell mediated cancer cell death [43]. 
This process might likely to involve exosome signaling, but such a hypothesis remains to be 
demonstrated. 
 
Modification of Content via Treatment of Isolated Exosomes 
Loading exosomes with endogenous or exogenous content (Box 2) following exosome purification has 
been evaluated for effectiveness against Huntington’s, Parkinson’s and Alzheimer’s diseases [44,45]. 
Insertion of siRNA targeting BACE1 in DC-derived exosomes resulted in targeted suppression of BACE1 
mRNA and protein in wild-type neuronal cells in mouse brains [46]. In addition, peptide antigens were 
shown to enhance immune responses in mice where ovalbumin-loaded exosomes induced T-cell 
proliferation in vitro and in vivo [47]. Similarly, upon loading bone marrow-derived exosomes with 
lipid-derived molecules including α-galactosylceramide, NK cell and T-cell innate anti-tumoral immune 
responses were induced in vivo in a murine melanoma cancer model [48]. Another example is that of 
vexosomes, which are virus vector capsids associated with exosomes, which in the case of AAV have 
enabled efficient transgene expression in murine cerebellum Purkinje cells upon transduction [49]. 
Moreover, for drug delivery purposes, paclitaxel-encapsulated vesicles have been shown to be 
effectively delivered into multi-drug resistant murine lung carcinoma cells [50].  
 
Negative Effects of Exosome Exposure 
Whilst exosomes provide effective tools for transportation of anti-cancer drugs with lower toxicity 
[51], it is important to consider their function as immuno-stimulating or immuno-suppressing moieties 
[52]. Exosomes have been proposed to play a role in shaping the tumor microenvironment through 
their involvement in various biological processes including angiogenesis, immune escape, and 
triggering an epithelial-to- mesenchymal transition (EMT) leading to metastasis initiation [53]. For 
instance, melanoma-derived exosomes have been shown to transfer the C-Met oncoprotein to bone 
marrow progenitor cells, inducing vascular leakiness at pre-metastatic sites, and promoting metastasis 
in mouse tumor models [54]. They also appear to influence drug resistance; for instance, exosomes 
isolated from an adriamycin-resistant breast cancer cell lines have been found to transfer drug 
resistance to drug-sensitive human breast cancer cell lines upon delivery of miR-222 in vitro [55]. An 
association between exosomes and obesity-related insulin resistance has also been reported; in this 
study, adipocyte-derived exosomes were found to activate adipose-resident macrophages and secrete 
inflammatory cytokines (L-6 and TNF-alpha), leading to insulin resistance in a ob/ob obesity mouse 
model [56]. 
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Exosomes as Potential Biomarkers 
The opportunity to exploit exosomes as biomarkers is an area of intense investigation. Current trends 
are focused on specific internal micro RNA markers that can be detected by PCR, and surface protein 
markers. The first clinical exosome products to appear on the market are exemplified by the 
“ExoDx®Prostate (IntelliScore)” test for prostate cancer that analyses exosomes isolated from urine 
for RNA biomarkers, currently used in combination with conventional PSA diagnostic tests 
(http://www.exosomedx.com/prostate-cancer-0).  
Biobanking 
Being able to access an individual’s exosome profile through a biobank, would further our approaches 
to personalized medicine through detailed clinical classification of complex diseases including cancers 
and metabolic disease [57]. To enable this, a standardized international approach to exosome 
isolation, characterization and storage needs to be established. 
 
Benefits within Regulatory Frameworks  
The European Union and United States regulatory agencies consider human exosome-based 
therapeutics as biological medicinal products, and, depending on pre- or post-isolation manipulations 
-- such as the genetic-manipulation or cell expansion of parent cells -- might be classified as advanced 
therapy medicinal products (ATMPs) [58]. When compared to MSC therapies, exosomes might be able 
to overcome safety concerns surrounding continued MSC proliferation, whilst having the same 
therapeutic effect. Presumably, exosomes might present a lower risk than cell-based therapeutic 
approaches. Nevertheless, the limited number of clinical trials, (Tables 1-3) reflects the difficulties 
associated with fully understanding molecular functions triggered by exosomes in target cell 
responses, and highlights the continued need for mechanism of action studies. 
 
Future Outlook 
To fully exploit the potential of exosomes, it will be critical to accurately define the modes of delivery 
to diseased tissues, either via systemic or localized delivery, or via localized assembly (Box 3). These 
considerations may include transit to target tissues and uptake, as well as the precise composition of 
exosomes or synthetic similars. 
Exosome Dynamics in Circulation 
Following release of exosomes into the circulation (or upon injection), these can move to sites that 
are distant from their point of origin/introduction, as observed from experiments using fluorescently 
labeled exosomes to monitor accumulation of siRNA delivery to the murine brain [46].  Indeed, one 
study used exosomes functionalized with a luciferase (gLuc)-lactadherin fusion protein to track 
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exosomes in vivo, upon intravenous injection in murine models; whole body imaging data revealed 
that exosomes exhibited very short half-lives following systemic administration, with less than 5% of 
administered exosomes remaining in the serum at 5 min post-injection [59]. This report proposed that 
this might be due to rapid clearance of exosomes from the circulation and/or to organ sequestration 
(e.g. by the liver) [59]. Similarly, miR-155 was shown to traffic from CD63-enriched B cell-derived 
exosomes that had been loaded with synthetic miR-155, into murine liver, adipose tissue, lung and 
muscle, but were absent from the thymus and heart, with plasma levels peaking at 5 min [60]. 
Consequently, the biodistribution of engineered exosomes containing different markers has indicated 
that these exosomes are short-lived in the circulation and in organs (5-40 mins) [59]. 
 
Organotropism and Mechanisms of Exosome Uptake  
Signal transduction from exosomes to cells occurs through membrane fusion or endocytosis, where 
specific exosome surface molecules drive cell targeting and adhesion (Box 2). Many exosomes contain 
major histocompatibility complex (MHC) class I and class II molecules involved in antigen binding and 
presentation; however, the requirement for MHC components in targeting does not appear to be an 
absolute requirement, as MHCI-/- and wild type derived murine exosomes can both induce T cell 
responses  [61]. In addition, integrins, annexins and tetraspanins are also present in these exosomes 
[2,62]. For example, based on proteomic analyses, specific α- and β-integrin combinations, such as 
α6β4 and α6β1 have been reported to direct human lung cancer cell exosomes to organ-specific sites 
in mouse models (i.e. lung), preparing an area for metastasis by fusing with specific tissue -resident 
cells (e.g. fibroblasts and epithelial cells)  [63]. These integrins also induced S100 protein synthesis in 
recipient cells, thus promoting local pro-migratory and pro-inflammatory activity [63].  Thus, specific 
exosome membrane composition can lead to selective tropism as well as recognition by recipient cells 
[63]. 
 
Towards Synthetic Exosomes 
 
Exosomes possess significant advantages over synthetic nano-vesicles, carrying multiple surface 
ligands in native conformations for cell targeting. The complexity of exosome structures, and the 
relatively low quantities produced by cells, offers challenges that may be overcome through the 
development of semi-synthetic or synthetic systems. The generation of exosome-mimetic vesicles is 
an exciting and important prospect for future therapeutic approaches. Synthetic nanovesicles, 
fabricated by forcing cells through microfluidic channels, have been assessed for augmented 
proliferation in murine skin fibroblasts [64] and as RNA carriers [65]. Since these nanovesicles are 
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generated directly from cells by extrusion, they are made up of cellular components including plasma 
membrane, membrane proteins, and intracellular biomolecules generated by the original cells.  
Serial extrusion through filters with diminishing pore sizes has produced exosome-mimetic 
nanovesicles following the breakdown of monocytes or macrophages, enabling delivery of 
chemotherapeutics into malignant tumors following systemic administration in mice [66]. These cell-
derived nanovesicles presumably have an almost identical targeting ability relative to parent cells, 
maintaining plasma membrane topology and constituent proteins; they also exhibit similar 
characteristics to naturally occurring exosomes, including size and membrane composition (e.g. the 
CD63 membrane marker) [66]. Moreover, hybrid exosomes, synthesized by fusing cell membranes 
with liposomes through freeze-thawing techniques, and subsequent cellular uptake studies of these 
vesicles have confirmed that their delivery function can be modified by changing the lipid composition 
[67].  
Using a new de novo exosome synthesis system, a multi-component drug iNPG-pDox (injectable 
NanoParticle Generator with polymer-Doxorubicin conjugate), it may be possible to achieve long-term 
cures in preclinical murine models of triple-negative breast cancer with lung and liver metastases 
(human equivalent of 20+ years, disease-free) [68].  This drug’s multi-stage nature essentially mimics 
MVB [69]. Specifically, it is designed so that its components act in a prescribed time sequence to 
overcome metastasis-associated biological barriers, and deliver chemotherapeutic agents 
preferentially to the perinuclear region of cancer cells, thus escaping the multi-drug resistance action 
of cell membrane-based efflux pumps [70]. A key finding for this effect was that doxorubicin-
containing nanoparticles needed to be formed inside cancer cells, as it was not sufficient to inject 
them systemically in mouse models of metastatic breast cancer [70]. iNPG-pDox generates exosome-
like nanoparticles once it preferentially reaches the metastatic microenvironment, and  upon 
internalization by tumor cells, the nanoparticles are cleaved at the nuclei into doxycycline, avoiding 
excretion by drug efflux pumps [70].  Because of its similarity to physiological nanoparticles, iNPG-
pDox can effectively deliver a mortal blow to cancer cells with high efficacy to otherwise untreatable 
cancer lesions [70]. 
Collectively, these different approaches provide a logical basis for the generation of reconfigurable 
semi-synthetic or synthetic exosomes, thereby increasing pharmaceutical acceptability through a 
controllable assembly process. 
 
Concluding Remarks 
The potential value of exosomes as therapeutic systems is increasingly promising, and for many, the 
safety and feasibility has been demonstrated in clinical trials. Nevertheless, it is clear that further 
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robust studies are necessary to deliver clinical outcomes. Future steps include the fine-tuning of 
therapeutic payloads, as well as targeting behavior and bioinspired redesign. We anticipate that these 
steps may open exciting new avenues for therapeutic application and facilitate clinical translation of 
these multi-tasked sentinels (see Outstanding Questions and Box 4). Ultimately, bridging nature with 
synthetic biology and biophysics will uphold the natural evolvability of exosomes into reconfigurable 
therapeutic systems. 
Outstanding questions box 
 Characterization exosome content requires multiple analytical approaches; there is a 
significant challenge in relating the highly complex content of an individual exosome, or the 
heterogeneous content among exosomes, to the biological effect. Is full characterization 
required? Will regulatory agencies deem that unnecessary, and approve clinical use in a 
similar way to cell-based therapeutics based on functionality? 
 Recently, cancer cells treated with non-cytotoxic doses of decitabine (therapeutic 
epigenome modulator) have resulted in cytokine release, triggering immune-cell attraction, 
and subsequent cancer cell cytotoxicity.  It is likely that this ‘holy grail’ approach to cancer 
cell drug-initiated self-killing might also involve the release of modified exosomes, but this is 
a question that remains to be explored. 
 Do specific/clinically active exosomes exhibit target cell specificity and can we identify the 
responsible cell surface features? An increased understanding of the contribution of the 
biophysical properties of exosomes toward target cell recognition and reception (rather than 
simplistic receptor-driven principles), will likely inform our ability to modulate the properties 
of exosomes. 
 Polarized trafficking of exosomes through regulated cytoskeletal remodeling might enable a 
directed release of exosomes; it may also establish a concentration gradient corridor for 
their intercellular delivery. What will be the most direct approaches to determine this? 
 Where does the convergence lie between natural and synthetic exosomes? Might we 
consider the reconfiguration of autologous or allogenic exosomes, and/or the synthesis of 
more complex liposome-like structures? 
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Box 1. Biogenesis of the Exosome 
Exosomes were independently discovered in 1983 by P. Stahl [71] and R. Johnstone [72], when 
maturing red blood cells from rat and sheep were shown to jettison ~30-100nm diameter globules 
into the extracellular matrix. Receptor-bound transferrin was sequestered into nano-vesicles that 
formed inside bigger multi-vesicular endosomes (MVE), some of which fused with the cell membrane 
and discharged the transferrin containing nano-vesicles outside the cell [71]. Years later, those nano-
vesicles were termed “exosomes” [73] in order to differentiate this new class of organelle from 
endosomal shuttles. 
 
Exosomes are formed by invagination of the limiting membrane of “sorting” vacuolar endosomes 
towards the lumen of these compartments, thus forming intraluminal vesicles (ILVs); endosomes are 
then referred to as MVEs or multi-vesicular bodies (MVBs) (Figure I) [62,74]. Across species, MVB and 
ILV formation is driven by the highly conserved, thirty protein subunit, endosomal sorting complex 
required for transport (ESCRT) complexes 0-III ESCRT-0, -I, -II and -III) [75]. An alternate mechanism 
also exists where lipids generated in the limiting membrane of MVBs induce inward budding, thus 
forming  ILVs in an ESCRT-independent manner [76].  Analysis of exosome content released during rat 
reticulocyte maturation has revealed the existence of three distinct sorting pathways for proteins and 
lipids into exosomes [77]. The first pathway relies on the protein Alix and either ESCRT complexes 
and/or lysobisphosphatidic acid, while the second and third pathways are associated with membrane 
lipid microdomains enriched in ceramides, and aggregating factors such as lectins, respectively [77].  
 
The observation of the immunomodulatory function of B lymphocyte exosomes in triggering CD4+ 
specific T cell responses, revealed a role for exosomes as transporters of MHC class II-peptide 
complexes between immune cells [78]. Subsequently, exosome release from dendritic cells was 
demonstrated where exosomes expressing MHC class I, class II and T-cell costimulatory molecules 
were shown to suppress growth of established murine tumors in a T cell-dependent manner, paving 
the way for the clinical consideration of exosomes as cell-free ‘vaccines’ in cancer immunotherapy 
[41,79]. recently, exosomes were revealed to contain functional RNA (mRNA and microRNA (miRNA)) 
[80]. Moreover, when murine exosomes were transferred into human cells in vitro, murine proteins 
were detected in these cells, showing that mRNA shuttled via exosomes could be translated to 
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functional proteins[80]. Such exosomal RNA content was absent from the cytoplasm of donor cells, 
suggesting that  protein production stemmed exclusively from extracellular signaling [80]. 
 
Box 2. Regulating Targeted Exosome Uptake  
Exosome manipulation as a consequence of cell treatment with a specific targeting antigen has 
resulted in antigen display on the exosome surface. For instance, a study used exosomes carrying 
neuron-specific rabies viral glycoprotein (RVG) peptide on the membrane surface to “ship” opioid 
receptor mu (MOR) siRNA into mouse brains as a model to treat morphine addiction, further 
demonstrating the capacity of exosomes to cross the blood brain barrier [81]. Moreover, the 
expression, in two MHC type-distinct mouse cell lines of the target tumor antigen human MUC1 
(hMUC1) -- a glycoprotein (mucin) overexpressed in different types of tumors--  produced exosomes 
which expressed that same peptide on their surface [82]. These exosomes were capable of stimulating 
immune cells and suppressing of hMUC1-expressing tumor growth in mice in a MUC1-specific and 
dose-related manner [82]. Another study showed that exosomes surface-armed with TRAIL (TNF-
Related Apoptosis-Inducing Ligand) targeted different tumor types, inducing apoptosis and inhibiting 
cell growth in tumor-bearing mice [83]. Others have also reported that the display of exosomal 
membrane protein (Lamp2b) fused to αv integrin-specific iRGD peptide, could deliver Doxorubicin to 
αv integrin-positive breast cancer cells in mice [26]. To enhance this approach, glycosylation motifs 
have since been introduced at various positions in surface antigens in cell lines, arresting protease 
mediated degradation, and enhancing targeting-antigen stability, whilst retaining their ability to 
interact with target proteins [80]. As such, the concept of the exosome glycome  has emerged [81], in 
which assumes that the glycome contributes significantly to exosome function, including the control 
of surface charge through  modulation of silicate molecules on glycan structures in the cell membrane 
[1]. 
Other techniques have been developed to enrich exosome surfaces, including Exosome Display, a 
methodology that exploits the ability to express non-naturally occurring proteins on these vesicles 
[84]. This approach has proved to be resourceful for engineering exosome surfaces to display 
multimeric, trans-membrane or soluble antigens which are not normally present. For instance, 
exosome-surface localized lactadherin has been achieved by binding its C1C2 domain to exosome 
lipids; as such, antigens or extracellular domains of membrane proteins can be displayed on exosomes 
after fusion with the C1C2 domain, and this has been used in the fabrication of anti-tumor antibodies 
[84,85]. Similarly, Click Chemistry has proved efficient for the conjugation of small molecules, such as 
Azide-Fluor 545, to the exosome surface, showing no alteration of the size or association of small 
molecules with recipient cells, and ensuring a reliable functionalization method [86]. 
 
Box 3. Force-Generating Mechanisms of Exosome Secretion 
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The involvement of actin and actomyosin-mediated forces in exosome secretion in invasive cancer 
cells occurs from protrusive actin-rich structures called invadopodia that establish docking sites for 
MVBs [87–89]. By inhibiting actin polymerization at invadopodia sites, polarized delivery of MVBs to 
invadopodia and exosome secretion can become impaired [87,88]. 
The regulation of actin filament dynamics is a means of exosome secretion modulation in different 
cancer model systems. Cortactin, an activator of the actin polymerizing complex Arp2/3 has been 
shown to enhance MVBs docking at the plasma membrane with subsequent exosome release; this 
occurs via assembly and stabilization of actin filament branches in invadopodia-like structures [90]. Of 
note, cortactin knockdown or overexpression in head or neck squamous cancer cells in vitro has been 
shown to induce the release of exosomes from invadopodia without altering significantly exosome 
biogenesis [90,91]. Actomyosin-mediated contractility at the cell cortex has also been reported to 
facilitate actin-bound MVB movement toward the plasma membrane by a mechanism that depends 
on the pulling force of non-muscle myosin II on the sides of future docking sites for MVBs [87,92–94]. 
Such subcellular dynamics are dependent on interactions with cytoskeleton-based force generating 
systems (such as microtubules, actin and actomyosin),  which is in turn are regulated by Rab proteins 
and their effectors [95].  At initial maturation stages, endosomes are transported along microtubules 
to the center of the cell by dynein/dynactin molecular motors[95], whereas translocation of MVBs to 
the plasma membrane requires kinesin-dependent movement towards microtubule plus ends [87], in 
coordination with actin and actomyosin cytoskeleton, GTPases and lipid second-messengers [87,95]. 
In polarized cells, such as lymphocytes, neurons and epithelia, specific lipid components, including 
cholesterol, sphingomyelin, and phosphoinositides domains of the plasma membrane harbor an 
increased capacity to recruit specific proteins that regulate the cytoskeleton, as well as those within 
signaling cascades that control vesicle tethering, membrane fusion and excision (Figure II) [96,97]. 
The docking and fusion of MVBs to specific points in the plasma membrane strongly depend on the 
structural organization and polarity of the cytoskeletal trafficking machinery, as well as on lipid 
composition and distribution; consequently, regulating these functions and properties may indeed  
lead to advantageous delivery of exosomes for signal confinement and enhanced uptake by recipient 
cells [95]. 
 
Box 4. Clinician’s Corner  
·        Exosomes, 30-100nm extracellular vesicles produced by all cells in the body, are biological 
signaling systems that function to facilitate short and long range intercellular communication 
including the transfer of molecules (DNA, RNA, proteins, lipids) and therefore molecular information 
between cells. 
·        Exosomes are being evaluated for their potential as disease specific biomarkers, vectors for 
drug delivery, and therapeutic agents per se, with clinical trials currently being undertaken for these 
applications. 
·        GMP stem cells therapeutics have the potential to also provide excellent sources of therapeutic 
exosomes. For example, when cultured in specific media CTX cells from ReNeuron have been shown 
to preferentially enrich a set of microRNAs contained within their exosomes which demonstrate 
anti-cancer properties in pre-clinical models. 
·        Exosomes could be responsible for problems associated with lack of response to current 
therapeutic approaches. HER2 presenting exosomes have been isolated from HER2-expressing 
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breast cancer models, and inhibition of Trastusumab activity through the presence of these 
exosomes has been shown. By extension this could also lead to decrease in activity to the ADC 
Trastuzumab emtansine (Kadcyla®). 
 
Glossary  
Nanoparticles: particles with dimensions ranging from 1 to 100nm. 
Multi-vesicular endosomes (MVE): Intra-luminal vesicles formed by inward budding of endosomal 
membranes as a function of the ESCRT machinery. 
Amphiphilic: a term describing a chemical compound possessing both hydrophilic 
and lipophilic properties. 
Opsonization: a process in which a supramolecular structure is functionalized or coated with a 
substance called an opsonin, marking the structure for selective cell or tissue recognition. 
Reticuloendothelial system (RES): also known as macrophage system, is a part of the 
immune system that consists of the phagocytic cells located in reticular connective tissue. 
Colloidal stability: a physical state that characterizes the relative ability of particles to remain 
dispersed in solution at equilibrium. 
Vexosomes: endogenously enveloped adeno-associated virus (AAV) vectors into exosomes. 
Exosome Display: a methodology enabling the manipulation of exosome protein content based on 
the identification of specific protein domains that mediate the distribution of proteins on exosomes. 
Click Chemistry: organic chemistry methodology that uses highly reliable and selective reactions 
designed to rapidly join small modular units together in high yield, without offensive by-products. 
Anisotropic: describes physical properties of a structure that exhibits different values depending on 
the direction from which they are measured. 
Invadopodia:  actin-rich protrusions of the plasma membrane; they are associated with degradation 
of the extracellular matrix in cancer invasiveness and metastasis. 
 
Figure legends 
Figure 1. The Multi-Faceted Exosome. Exosomes are composed of two major functional 
compartments, the external bilayer (yellow circle) and the internal ‘cargo bay’. Exosomes can be 
broadly classified into two groups; native (produced internally by an organism) or modified externally 
(blue arrows), through cell growth in conditioning media, reprogramming of content and/or 
membrane composition by cell treatment with external agents (drugs, genetic modification), and 
loading of novel content (blue boxes). Exosomes, administered exogenously, or endogenously from 
implanted or endogenous cells, can have short or long distance effects targeting specific cells and 
inducing a positive molecular modulation (e.g. triggering cancer cell death) to the target (green) as a 
function of either exosome content or bilayer composition/biophysical effect. In addition exosomes 
have also been shown to activate immune responses to initiate immune-protective functions. 
Exosomes can also have a negative effect, including pacifying the immune system so as for diseased 
cells to evade recognition, and in triggering the establishment of niche environments for metastatic 
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cancer. Such exosomes as well as others simply originating from diseased cells, but without yet a 
defined function, will make effective biomarkers for disease identification and monitoring. 
 
Figure I (in Box 1). The Formation of Exosomes. Inward budding of the plasma membrane originates 
the formation of early endosomes (not shown), which then mature into late endosomes or multi-
vesicular bodies (MVBs). Intraluminal vesicles (ILVs) are generated by invagination of MVBs. MVBs 
release their content extracellularly after fusion with the plasma membrane, and secreted ILVs are 
now, designated exosomes. Inset: transmission electron microscopy image of neural stem cells 
releasing extracellular vesicles of various sizes. Scale bar corresponds to 1μm.  “Courtesy of ReNeuron, 
UK”.  
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Figure II (in Box 2). Cell Manipulation for Polarized Exosome Secretion. Exosome release normally 
occurs following the fusion of MVBs at random points in the cell membrane due to the anisotropic 
arrangement of the cytoskeleton along which MVBs transit (top). The establishment of actin-rich 
invadopodia targets MVBs, directing exosome release (bottom), which can be inhibited by blocking 
the function of cortactin.  Direction of MVB and exosome movement/transport (arrows). 
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Table 1. Current or Recently Completed Registered NIH Clinical Trials Involving Exosomes as 
Diagnostic Agents (clinicaltrials.gov).  
Study Title Disease Study Design Start Date Reference 
Circulating Exosome As Potential Prognostic  
And Predictive Biomarkers In Advanced  
Gastric Cancer Patients: A Prospective  
Observational Study ("EXO-PPP Study")  
Gastric Cancer  Prospective Trial  
Observational  
Phase not provided  
(currently recruiting)  
Jan 2013  NCT01779583 
 
An Observational, Single-Institution  
Pilot/Feasibility Study of Exosome Testing as a 
Screening Modality for Human  
Papillomavirus-Positive Oropharyngeal Squamous Cell 
Carcinoma  
Oropharyngeal 
Cancer  
  
Prospective Trial  
Observational  
Phase not provided  
(currently recruiting)  
Feb 2015  NCT02147418 
 
LRRK2 and Other Novel Exosome Proteins in  
Parkinson's Disease  
Parkinson’s 
Disease  
Prospective Trial  
Observational  
Phase not provided  
(ongoing, not 
recruiting)  
Jan 2013  NCT01860118 
 
Clinical Research for the Consistency Analysis of PD-L1 
in Cancer Tissue and Plasma Exosome   
Non-small cell 
lung cancer  
  
Prospective Trial   
Interventional  
Phase not provided  
Oct 2016  NCT02890849 
 
Clinical Research for the Consistency Analysis of PD-L1 
in Lung Cancer Tissue and Plasma Exosome Before and 
After Radiotherapy  
Non-small cell 
lung cancer  
  
Prospective Trial   
Interventional  
Phase not provided  
Oct 2016  NCT02869685 
 
Pilot Study With the Aim to Quantify a Stress Protein in 
the Blood and in the Urine for Early 
Diagnosis of Malignant Solid Tumors 
Breast cancer, 
ovarian cancer,   
non-small cell 
lung cancer. 
Interventional  
Phase not provided  
  
Sep 2015  NCT02662621 
 
Detection of Circulating Biomarkers of Immunogenic 
Cell Death After Radiotherapy and Chemotherapy: An 
Exploratory Study 
Non Small Cell 
Lung Cancer  
  
Interventional  
Phase not provided  
  
Nov 2016  
  
NCT02921854 
 
Early Biomarkers of Tumor Response in High Dose 
Hypofractionated Radiotherapy Word, Package 3: 
Immune Response 
Carcinoma,  
Hepatocellular  
Colorectal 
Neoplasms  
Melanoma  
Kidney 
Neoplasms  
Interventional  
Phase not provided  
  
Sep 2015  
  
NCT02439008 
 
Anaplastic Thyroid Cancer and Follicular Thyroid 
Cancer-derived Exosomal Analysis Via 
Treatment of Lovastatin and Vildagliptin and Pilot 
Prognostic Study Via Urine Exosomal 
Biological Markers in Thyroid Cancer Patients 
Thyroid Cancer  
  
Prospective Trial  
Observational  
Phase not provided  
  
Aug 2016  NCT02862470 
 
NCT - ClinicalTrials.gov registry number 
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Table 2. Current or Recently Completed Registered NIH Clinical Trials Involving Exosomes as 
Therapeutic Agents (clinicaltrials.gov).  
NCT - ClinicalTrials.gov registry number 
 
  
Study Title Disease Study Design Start Date Reference 
Effect of Plasma Derived Exosomes on  
Intractable Cutaneous Wound Healing: Prospective 
Trial  
Ulcer  Prospective Trial   
Interventonal 
Phase 0  
Sep 2015  NCT02565264 
 
Phase I Clinical Trial Investigating the Ability of Plant 
Exosome to Deliver Curcumin to  
Normal and Malignant Colon Tissue  
Colon Cancer  Clinical Trial  
Interventional 
Phase 1  
Jan 2011   
NCT01294072 
 
Phase 1 Study of The Effect of Cell-Free Cord  
Blood Derived Microvesicles On β-cell Mass in Type 1 
Diabetes Mellitus (T1DM) Patients  
Diabetes 
Mellitus Type  
1  
  
Clinical Trial  
Interventional 
Phase 2  
Phase 3  
Apr 2014  NCT02138331 
 
Preliminary Clinical Trial Investigating the Ability of 
Plant Exosomes to Abrogate Oral Mucositis Induced by 
Combined  
Chemotherapy and Radiation in Head and Neck Cancer 
Patients  
Head and Neck 
cancer Oral 
Mucositis  
Preliminary Clinical Trial  
Interventional 
Phase 1  
Aug 2012  NCT01668849 
 
Vaccination of metastatic melanoma patients with 
autologous dendritic cell (DC) derived exosomes: 
results of the first phase I clinical trial  
Melanoma  Clinical Trial  
Interventional 
Phase 1  
Mar 2005  
 
[99] 
A phase I study of exosome immunotherapy in patients 
with advanced non-small cell lung  
cancer  
Lung Cancer  Clinical Trial   
Interventional 
Phase 1  
Feb 2005  
 
[98] 
Phase I clinical trial of autologous ascites derived 
exosomes combined with GM-CSF for colorectal cancer  
Colorectal 
Cancer  
Clinical Trial   
Interventional  
Phase 1  
  
Apr 2008  [100] 
 
Phase II Trial of a Vaccination With Tumor Antigen-
loaded Dendritic Cell-derived Exosomes on Patients 
With Unresectable Non Small Cell Lung Cancer 
Responding to Induction Chemotherapy 
Non Small Cell 
Lung Cancer  
Clinical Trial   
Interventional  
Phase 2  
  
  
Dec 2009  
 
NCT01159288 
 
Phase II Study of Tumor Cell-derived Microparticles 
Used as Vectors of Chemotherapeutic Drugs to Treat 
Malignant Ascites and Pleural Effusion  
Malignant 
Pleural Effusion  
Malignant 
Ascites  
Clinical Trial   
Interventional  
Phase 2  
  
May 2013  NCT01854866 
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Table 3. Current or Recently Completed Registered NIH Clinical Trials Involving Exosomes as 
Observational and Molecular Mechanisms (clinicaltrials.gov).  
NCT - ClinicalTrials.gov registry number 
Study Title Disease Study Design Start Date Reference 
Pilot Study of Exosomes Before and After BRAF 
Inhibitor Therapy in Patients With Advanced 
Unresectable or Metastatic BRAF Mutation-positive 
Melanoma  
Metastatic 
Melanoma  
  
Interventional  
Phase not provided  
  
Dec 2014  
  
NCT02310451 
 
Isolation and Characterization of the Extracellular 
Vesicles Secreted by the Human Endometrium to the 
Endometrial Fluid  
Healthy  Prospective Trial   
Observational  
Phase not provided  
  
Apr 2016  
  
NCT02797834 
 
